Videos

Bobby Liaw, MD; Vivek K. Narayan, MD, MS; Ashley E. Ross, MD, PhD; and Neal Shore, MD, FACS, provide closing thoughts and advice for the optimal management of advanced prostate cancer.

Experts in prostate cancer review the role of PSMA PET imaging in advanced prostate cancer and its impact on disease management.

Bobby Liaw, MD, and Vivek K. Narayan, MD, MS, share clinical pearls for the management of adverse events from ARI-directed therapy in advanced prostate cancer.

Urology Times® Co–Editor in Chief Michael S. Cookson, MD, MMHC, recaps 5 presentations from the 2022 Genitourinary Cancers Symposium.

“The traction on this, I think, is really rather remarkable,” says Neal D. Shore, MD, FACS.

“I view OAB as a problem for many women that hasn't gotten the attention that it's needed over the decades,” says Alexandra Rogers, MD.

“I think one important message here is that MTAP is an important novel pathway in carcinogenesis, particularly bladder and urothelial carcinomas,” says Philippe E. Spiess, MD, MS, FRCSC, FACS.

“We should be really trying to raise the profile of bladder symptoms [and] functional urology issues, and educating colleagues on how to inquire about and capture that information as effectively as possible,” says Jai Seth, MD, BSc, MSc, FRCS.

Abstracts highlight topics such as sacral neuromodulation and percutaneous tibial nerve stimulation.

“I think results from this study introduce a new standard of care for patients with metastatic hormone-sensitive prostate cancer, where we clearly need to do better than what we're doing today, since the sequence of therapy seems to be less effective than hitting them hard upfront,” says Fred Saad, MD, FRCS.

"Active surveillance is an innovation because it's truly a departure from the idea that all prostate cancers or cancer, in general, needs to be treated," says Kara L. Watts, MD.

Experts discuss tibial nerve stimulation, an emerging treatment for OAB.

Overactive bladder experts discuss when they move from one treatment to another, and share pros and cons of available third-line treatments.

The device is indicated for overactive bladder, chronic fecal incontinence, and non-obstructive urinary retention.

“I think initiating a conversation with a patient needs to start earlier, possibly even earlier than just at the point of giving them a diagnosis,” says Netty Kinsella, RN, MSc, PhD.

“The proportion of clinics that employ an onsite urologist, where the urologist is integrated into the flow of that clinic, is relatively small,” says Akanksha Mehta, MD, MS.

“The majority of patients were able to stay on the dose of the apalutamide,” says Mario E. Lacouture, MD.

Janet Kukreja, MD, recaps 5 presentations from the 2022 Genitourinary Cancers Symposium.

“Whether a patient goes on to have radiation therapy, radical surgery, or focal therapy, or a whole host of other types of surgery or prostate cancer treatment that may follow, [that] can largely dictate where they may end up on the spectrum of having a bladder problem, a bladder outlet problem, or a urethral problem,” says Jai Seth, MD, BSc, MSc, FRCS.

“I think we're at a point where we have this luxury of many options, which is great, but we still need to continue to be really thoughtful in how we choose those options,” says Benjamin Lowentritt, MD, FACS.

“I think the audience would be encouraged to know that in the future, it seems like immunotherapy would become the standard of care,” says Shilpa Gupta, MD.

“I think that we keep getting better and better tools…[and] I think understanding how to utilize these tools will be a challenge in the future,” says David M. Schuster, MD, FACR.

“The idea is to develop strategies that reduce the likelihood of needing a biopsy or improving the sensitivity of the biopsy to find a high-grade cancer, one that's treatable,” says Eric A. Klein, MD.

“The management of hereditary upper tract cancer and Lynch syndrome [is] a multidisciplinary approach,” says Hong Truong, MD.

Ashley E. Ross, MD, PhD, comments on the clinical significance of PSA response in patients with nmCRPC.

Vivek K. Narayan, MD, MS, reviews data from the SPARTAN trial in nmCRPC and discusses the importance of assessing health-related quality of life.

Ashley E. Ross, MD, PhD, discusses challenges and unmet needs in managing nmCRPC and Bobby Liaw, MD, reviews the PROSPER and ARAMIS trials.

“We need to look at tumors a little bit differently. Not so much put them in the same categories, but really look at them based on whether the mutation is as identified in that specific marker,” says Philippe E. Spiess, MD, MS, FRCSC, FACS.

“I think that [these findings] definitely [warrant] standard of care radiation and hormone therapy for these patients or other forms of radical therapy,” says Daniel E. Spratt, MD.

“Patients are interested in exercise, they're really keen, they want to know what they can do to help themselves,” says Kerry S. Courneya, PhD.